文献速递中医内科中药与中成药合理使用

桃红四物汤治疗心绞痛的疗效与安全性Meta分析

Efficacy and Safety Evaluation of Taohong Siwu Decoction () for Patients with Angina Pectoris: A Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Chin J Integr Med · 2019-04-02

该Meta分析检索9个数据库至2017年3月,纳入12项随机对照试验共959例心绞痛患者,评估桃红四物汤联合常规治疗对比常规治疗的效果。结果显示联合治疗可改善心绞痛症状和心电图,并降低hs-CRP、TG、TC、LDL-C水平,未报告严重不良事件,但无研究报道主要心血管事件结局。

要点

  • 桃红四物汤联合常规治疗可改善心绞痛症状和心电图,且未报告严重不良事件。
  • 联合治疗可降低hs-CRP、TG、TC和LDL-C水平。
  • 无研究报道死亡、急性心肌梗死或靶血管血运重建等主要结局。

核心结论

  • 桃红四物汤联合常规治疗对缓解心绞痛有潜在获益且无显著不良事件,但心血管事件疗效需更严格的大规模多中心随机对照试验评估。

研究设计与样本

  • 检索PubMed、Cochrane图书馆、EMBASE、CNKI、CBM、万方、维普、中国临床试验注册中心和国际临床试验注册中心从建库至2017年3月的随机对照试验。
  • 纳入12项试验共959例心绞痛患者,比较桃红四物汤联合常规治疗与常规治疗加安慰剂或单用常规治疗。

主要发现

  • 联合治疗改善心绞痛症状的RR=3.70,95%CI(2.42,5.67)。
  • 联合治疗改善心电图的RR=3.20,95%CI(2.20,4.65)。
  • 联合治疗降低血清hs-CRP、TG、TC和LDL-C水平。
  • 联合治疗未报告严重不良事件。
  • 无研究报道死亡、急性心肌梗死和靶血管血运重建等主要结局。

关键数值与推荐

  • 主要结局为死亡、急性心肌梗死和靶血管血运重建的复合事件,但无研究报道。
  • 次要结局包括心绞痛症状、心电图改善及血清hs-CRP、ET-1、TG、TC和LDL-C水平。
  • 采用RevMan 5.3软件进行统计分析,计算RR和SMD及95%CI,并用漏斗图评估发表偏倚。

临床怎么用

  • 在常规治疗基础上可考虑联合桃红四物汤以缓解心绞痛症状和改善心电图。
  • 联合治疗可能有助于降低hs-CRP、TG、TC和LDL-C水平。
  • 对心血管事件硬终点的影响尚不明确,不能据此替代或改变常规心血管事件预防策略。

局限性

  • 无研究报道死亡、急性心肌梗死和靶血管血运重建等主要结局。
  • 纳入研究的方法学质量需评估,且样本量有限(12项试验共959例)。
  • 心血管事件疗效需未来更严格设计的大规模多中心随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of Taohong Siwu Decoction (, TSD), a Chinese herbal compound prescription, in patients with angina pectoris (AP). METHODS: Randomized clinical trials (RCTs) comparing TSD plus conventional treatment (CT) with CT plus placebo or CT only in the patients with AP were searched in PubMed, Cochrane Library, Excerpta Medica Database, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature Database, Wanfang Database, Chinese Scientific Journal Database, Chinese Clinical Trial Registry and International Clinical Trial Registry from their inception to March 2017. The primary outcomes include a composite event of death, acute myocardial infarction (AMI), and target vessel revascularization. The secondary outcomes include angina symptom, electrocardiogram (ECG) improvement and serum high-sensitivity C-reactive protein (hs-CRP), endothelin-1 (ET-1), triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels. The methodological quality of included studies and extracted available data were assessed. RevMan 5.3 software was used to conduct statistical analysis. The relative risk (RR) and standardized mean difference (SMD) with 95% confidence interval (CI) was calculated. A funnel plot was used to evaluate the publication bias. RESULTS: Among 204 studies identified in the literature search, 12 trials including 959 patients with AP met the inclusion criteria. No studies reported the primary outcome including death, AMI and target vessel revascularization. TSD combined with CT showed significant improvement in relieving angina symptom [RR=3.70, 95% CI (2.42, 5.67)] and ECG [RR=3.20, 95% CI (2.20, 4.65)] compared with CT alone. TSD combined with CT reduced the serum hs-CRP, TG, TC and LDL-C levels compared with CT alone. No serious adverse events were reported in TSD combined with CT. CONCLUSIONS: TSD combined with CT has a potential benefit on relieving AP without significant adverse events. However, the efficacy on the cardiovascular events needs to be assessed by more rigorously-designed, largescale, and multi-center RCTs in future.

来源:Chin J Integr Med,查看原文。版权归原作者所有。

引用

  1. Tao TQ, Mao HM, Xia L, et al. Efficacy and Safety Evaluation of Taohong Siwu Decoction () for Patients with Angina Pectoris: A Meta-Analysis of Randomized Controlled Trials. Chin J Integr Med. 2019. PMID: 30941683. doi:10.1007/s11655-019-3028-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。